Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Fog Pharmaceuticals is raising $107,000,017.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Gregory Verdine played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Fog Pharmaceuticals

FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that drug the undruggable. FogPharma’s cell-penetrating miniproteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together with world-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments.

To learn more about Fog Pharmaceuticals, visit http://fogpharma.com/

Contact:
Gregory Verdine, Chief Executive Officer
617-945-9510
gverdine@fogpharma.com
https://www.linkedin.com/in/greg-verdine-b181991/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved